Ritonavir and Rivaroxaban interaction

Ritonavir and Rivaroxaban: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Ritonavir (Norvir) label · effective 2026-07-23

Major

Anticoagulant: rivaroxaban ↑ rivaroxaban Avoid concomitant use of rivaroxaban and ritonavir.

Drug interactionsby drug classView label on DailyMed
Moderate

Co-administration of ritonavir and rivaroxaban may lead to risk of increased bleeding.

Drug interactionsnames RivaroxabanView label on DailyMed
Moderate

Anticoagulant: warfarin ↑↓ warfarin Initial frequent monitoring of the INR during ritonavir and warfarin co-administration is recommended.

Drug interactionsby drug classView label on DailyMed

From the Rivaroxaban (Xarelto) label · effective 2026-08-12

Major

Use with P-gp and Strong CYP3A Inhibitors or Inducers Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A inhibitors [see Drug Interactions (7.2) ] .

Warnings and precautionsby drug classView label on DailyMed
Major

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] .

Warnings and precautionsby drug classView label on DailyMed
Major

• Avoid combined P-gp and strong CYP3A inhibitors and inducers ( 7.2 , 7.3 )

Drug interactionsby drug classView label on DailyMed
Major

Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems Interaction with Combined P-gp and Strong CYP3A Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ] .

Drug interactionsby drug classView label on DailyMed
Major

Interaction with Combined P-gp and Moderate CYP3A Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to <80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical…

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.